Tin tức & Cập nhật

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Hepatic venous pressure gradient (HVPG)-guided prophylaxis with non-selective beta blockers (NSBB) seems to be reasonably effective in patients with nonalcoholic steatohepatitis (NASH), eliciting responses from around half of this population, a recent study has found.

In the phase IIb NATIVE* trial, the pan-PPAR** agonist lanifibranor demonstrated histologic benefits for patients with nonalcoholic steatohepatitis (NASH).

Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.

Bariatric surgery significantly lowers the risk of major adverse liver outcomes and major adverse cardiovascular events (MACE) – the dual primary endpoints – in obese patients with biopsy-driven nonalcoholic steatohepatitis (NASH) in the SPLENDOR* study.

Metabolic dysfunction-associated fatty liver disease contributes to an increased risk of subsequent unfavourable pregnancy outcomes, a study reports.

Access to liver transplantation suffers from a persistent and unacceptable gender gap, with female candidates on the wait list being much less likely to receive a transplant and facing a higher risk of dying than their male counterparts, according to an expert.